Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Current Deferred Revenue (2019 - 2025)

Silence Therapeutics' Current Deferred Revenue history spans 7 years, with the latest figure at $168000.0 for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 45.1% year-over-year to $168000.0; the TTM value through Dec 2025 reached $168000.0, down 45.1%, while the annual FY2025 figure was $168000.0, 45.1% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $168000.0 at Silence Therapeutics, down from $301000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $10.4 million in Q4 2022 and bottomed at $168000.0 in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $424500.0 (2025), against an average of $3.0 million.
  • The largest annual shift saw Current Deferred Revenue soared 81.6% in 2022 before it plummeted 95.22% in 2024.
  • A 5-year view of Current Deferred Revenue shows it stood at $5.7 million in 2021, then skyrocketed by 81.6% to $10.4 million in 2022, then plummeted by 38.39% to $6.4 million in 2023, then crashed by 95.22% to $306000.0 in 2024, then plummeted by 45.1% to $168000.0 in 2025.
  • Per Business Quant, the three most recent readings for SLN's Current Deferred Revenue are $168000.0 (Q4 2025), $301000.0 (Q3 2025), and $457000.0 (Q2 2025).